iCAD (ICAD) Competitors $1.96 +0.07 (+3.42%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends ICAD vs. OBIO, LAKE, SKIN, BWAY, KRMD, INFU, SGHT, PDEX, TLSI, and NVROShould you be buying iCAD stock or one of its competitors? The main competitors of iCAD include Orchestra BioMed (OBIO), Lakeland Industries (LAKE), Beauty Health (SKIN), BrainsWay (BWAY), KORU Medical Systems (KRMD), InfuSystem (INFU), Sight Sciences (SGHT), Pro-Dex (PDEX), TriSalus Life Sciences (TLSI), and Nevro (NVRO). These companies are all part of the "medical equipment" industry. iCAD vs. Orchestra BioMed Lakeland Industries Beauty Health BrainsWay KORU Medical Systems InfuSystem Sight Sciences Pro-Dex TriSalus Life Sciences Nevro iCAD (NASDAQ:ICAD) and Orchestra BioMed (NASDAQ:OBIO) are both small-cap computer and technology companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, dividends, institutional ownership, community ranking, earnings, valuation and analyst recommendations. Does the media favor ICAD or OBIO? In the previous week, iCAD had 1 more articles in the media than Orchestra BioMed. MarketBeat recorded 1 mentions for iCAD and 0 mentions for Orchestra BioMed. iCAD's average media sentiment score of 0.95 beat Orchestra BioMed's score of 0.00 indicating that iCAD is being referred to more favorably in the media. Company Overall Sentiment iCAD Positive Orchestra BioMed Neutral Which has preferable earnings & valuation, ICAD or OBIO? iCAD has higher revenue and earnings than Orchestra BioMed. iCAD is trading at a lower price-to-earnings ratio than Orchestra BioMed, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioiCAD$17.32M3.01-$4.85M-$0.13-15.12Orchestra BioMed$2.76M72.71-$49.12M-$1.61-3.28 Do insiders & institutionals believe in ICAD or OBIO? 24.6% of iCAD shares are held by institutional investors. Comparatively, 53.6% of Orchestra BioMed shares are held by institutional investors. 10.3% of iCAD shares are held by company insiders. Comparatively, 6.7% of Orchestra BioMed shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Does the MarketBeat Community believe in ICAD or OBIO? iCAD received 216 more outperform votes than Orchestra BioMed when rated by MarketBeat users. However, 100.00% of users gave Orchestra BioMed an outperform vote while only 62.13% of users gave iCAD an outperform vote. CompanyUnderperformOutperformiCADOutperform Votes22862.13% Underperform Votes13937.87% Orchestra BioMedOutperform Votes12100.00% Underperform VotesNo Votes Do analysts prefer ICAD or OBIO? Orchestra BioMed has a consensus target price of $16.25, suggesting a potential upside of 207.77%. Given Orchestra BioMed's stronger consensus rating and higher possible upside, analysts clearly believe Orchestra BioMed is more favorable than iCAD.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score iCAD 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Orchestra BioMed 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility and risk, ICAD or OBIO? iCAD has a beta of 1.4, suggesting that its stock price is 40% more volatile than the S&P 500. Comparatively, Orchestra BioMed has a beta of 0.53, suggesting that its stock price is 47% less volatile than the S&P 500. Is ICAD or OBIO more profitable? iCAD has a net margin of -17.81% compared to Orchestra BioMed's net margin of -2,179.33%. iCAD's return on equity of -15.65% beat Orchestra BioMed's return on equity.Company Net Margins Return on Equity Return on Assets iCAD-17.81% -15.65% -12.52% Orchestra BioMed -2,179.33%-107.04%-70.88% SummaryiCAD beats Orchestra BioMed on 11 of the 18 factors compared between the two stocks. Get iCAD News Delivered to You Automatically Sign up to receive the latest news and ratings for ICAD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ICAD vs. The Competition Export to ExcelMetriciCADSurgical & medical instruments IndustryComputer SectorNASDAQ ExchangeMarket Cap$52.15M$4.71B$27.12B$9.14BDividend YieldN/A47.30%2.78%4.02%P/E Ratio-15.1226.29236.9017.36Price / Sales3.0158.293,720.9977.11Price / CashN/A50.1434.3235.97Price / Book1.557.798.394.79Net Income-$4.85M$13.87M$669.90M$225.00M7 Day Performance2.88%1.53%3.66%2.62%1 Month Performance7.38%10.34%4.89%3.81%1 Year Performance27.60%32.32%24.37%20.10% iCAD Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ICADiCAD1.0458 of 5 stars$1.97+3.4%N/A+27.6%$52.15M$17.32M-15.12140Short Interest ↓Gap DownHigh Trading VolumeOBIOOrchestra BioMed1.996 of 5 stars$5.18-5.3%$15.80+205.0%-39.4%$196.91M$2.65M-3.224LAKELakeland Industries4.172 of 5 stars$25.70-2.0%$27.50+7.0%+48.7%$190.33M$151.82M-285.561,750Analyst ForecastSKINBeauty Health1.948 of 5 stars$1.51-2.6%$2.55+69.0%-28.4%$187.34M$347.62M-3.591,030Positive NewsBWAYBrainsWay3.6537 of 5 stars$9.73+3.5%$13.17+35.3%+60.6%$183.05M$38.63M97.31120KRMDKORU Medical Systems2.7917 of 5 stars$3.86-2.5%$4.13+6.9%+97.6%$176.93M$31.99M-15.4480Analyst ForecastShort Interest ↓Positive NewsHigh Trading VolumeINFUInfuSystem1.5647 of 5 stars$7.82+3.7%$13.00+66.2%N/A$166.28M$132.78M130.36410SGHTSight Sciences3.5164 of 5 stars$3.21-1.2%$5.12+59.5%-45.0%$162.92M$79.54M-3.15210Gap DownPDEXPro-Dex3.473 of 5 stars$46.76-0.4%$52.00+11.2%+110.0%$152.39M$56.80M30.36140Insider TradePositive NewsTLSITriSalus Life Sciences3.8114 of 5 stars$4.96-3.9%$11.79+137.6%-42.3%$151.25M$26.89M-1.99106Gap DownNVRONevro2.6641 of 5 stars$3.89+18.2%$6.30+62.0%-75.4%$145.77M$419.15M-2.061,215Gap Up Related Companies and Tools Related Companies Orchestra BioMed Alternatives Lakeland Industries Alternatives Beauty Health Alternatives BrainsWay Alternatives KORU Medical Systems Alternatives InfuSystem Alternatives Sight Sciences Alternatives Pro-Dex Alternatives TriSalus Life Sciences Alternatives Nevro Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ICAD) was last updated on 1/20/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is ...Brownstone Research | SponsoredKamala’s final humiliation The investments connected to Trump's second term in ways that almost nobody outside his inner circle is aware ...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredWarren Buffett Bets $40 Billion—You Can Get in for $20I call it "The Last Retirement Stock You'll Ever Need." Warren Buffett himself owns $40 billion of stock in...Behind the Markets | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementThe #1 Coin Poised to Soar Under Trump Pro-Crypto White House could make this the investment opportunity of...Crypto 101 Media | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding iCAD, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share iCAD With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
